Zhejiang Hisun Pharmaceutical Co., Ltd.

Overview

Zhejiang Hisun Pharmaceutical Co., Ltd. is a leading pharmaceutical company in China dedicated to the research, development, manufacturing, and distribution of a wide array of therapeutic drugs. With a strong focus on innovation and quality, Hisun aims to improve health by providing effective and accessible medications worldwide.

Therapeutic areas

API / Drug Master Files

Zhejiang Hisun Pharmaceutical Co., Ltd. holds 311 active (464 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• OSIMERTINIB MESYLATEActive2026-03-31
• TRAMETINIBActive2026-03-21
• LINACLOTIDEActive2026-03-16
• DIPHENHYDRAMINE HYDROCHLORIDEActive2026-03-11
• GABAPENTINActive2026-03-05
• CEFDINIRActive2026-02-05
• TRAMETINIB DIMETHYL SULFOXIDEActive2026-01-30
• SACUBITRIL SODIUMActive2026-01-23
• TRICLOSANActive2026-01-16
• BIMATOPROSTActive2026-01-14
• ROSUVASTATIN CALCIUM INTERMEDIATE (R-2) (PROCESS 2)Active2025-12-31
• APALUTAMIDEActive2025-12-30
• RESMETIROMActive2025-12-26
• ORITAVANCIN NUCLEUS ACETATEActive2025-12-26
• ETODALACActive2025-12-22

Showing 15 of 464 Drug Master Files.

FDA compliance signals